| Trial Identifier: | 208887 Sub Study 5 |
| Sponsor: | GlaxoSmithKline |
| Start Date: | July 2021 |
| Primary Completion Date: | April 2025 |
| Study Completion Date: | March 2027 |
| Condition: | Myeloma |
For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.
| Language | Description |
| Country | Location |
|---|---|
| Australia, VIC | Fitzroy, VIC, Australia, 3065 |
| Brazil, Bahia | Salvador, Bahia, Brazil, 41253-190 |
| Brazil, Sao Paulo | Sao Paulo, Brazil, 04537-080 |
| Canada, Ontario | Toronto, Ontario, Canada, M5G 2M9 |
| France | VILLEJUIF CEDEX, France, 94805 |
| Greece, NA | Athens, NA, Greece, 11528 |
| Korea, Republic of | Seoul, Korea, Republic of, 06351 |
| Korea, Republic of | Seoul, Korea, Republic of, 06591 |
| Korea, Republic of | Ulsan, Korea, Republic of, 44033 |
| Mexico, Mexico City | Mexico City, Mexico, 01330 |
| Norway | Oslo, Norway, 0450 |
| Spain | Madrid, Spain, 28041 |
| Spain | Madrid, Spain, 28040 |
| Spain | Pozuelo de AlarcOn Madr, Spain, 28223 |
| Sweden | FALUN, Sweden, SE-791 82 |
| United States, GA | Atlanta, GA, United States, 30322 |
| United States, MA | Boston, MA, United States, 02215 |
| United States, MI | Grand Rapids, MI, United States, 49546 |
| United States, WI | Madison, WI, United States, 53792 |
Powered by
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.
Copyright © 2026 Pharma Intelligence UK Limited (Citeline), a Norstella company